Security key
45720N103
Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)
CUSIP: 45720N103
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 10,435,616
- Total 13F value
- $148,917,132
- Share change
- -385,573
- SEC-reported price per share
- $14.27
- Number of holders
- 87
- Value change
- -$5,468,523
- Number of buys
- 30
- Number of sells
- 48
- Shares outstanding
- 14,630,961
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
87
Top holders
10
INBX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Inhibrx Biosciences, Inc. SEC filings
Inhibrx Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 45720N103
Recent filing periods:
Ownership snapshot
Top reported holders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jon Faiz Kayyem
Disclosed value leader
VIKING GLOBAL INVESTORS LP
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 7.9%
13D/G row: Jon Faiz Kayyem
Showing 1-6 of 15 holder rows.
Quick read
Jon Faiz Kayyem leads the comparable SEC ownership view at 7.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jon Faiz Kayyem's linked filing trail.
Comparable ownership
Top 5
Jon Faiz Kayyem
7.9%
Mark P. Lappe
6.4%
VIKING GLOBAL INVESTORS LP
12%
Sanofi
7.9%
PERCEPTIVE ADVISORS LLC
7.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jon Faiz Kayyem |
13D/G
|
7.9%
|
$13,765,571
1,149,046 shares
|
$0 | 03 Jun 2024 |
| Mark P. Lappe |
3/4/5
13D/G
Chief Executive Officer, Director · Mark Lappe
|
6.4%
from 13D/G
|
$15,852,324
1,225,413 shares
mixed-class rows
|
— | 12 Sep 2024 |
| VIKING GLOBAL INVESTORS LP |
13F
Company
|
12%
|
$25,009,993
1,787,705 shares
|
— | 31 Mar 2025 |
| Sanofi |
13F
Company
|
7.9%
|
$16,199,385
1,157,926 shares
|
— | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
7.3%
|
$14,885,723
1,064,026 shares
|
— | 31 Mar 2025 |
| HighTower Advisors, LLC |
13F
Company
|
6%
|
$12,195,838
871,754 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
87
Shares
10,435,616
Rows available
87
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
92
Q2 2025 holders
87
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend